Morgan Stanley raised the firm’s price target on Tenet Healthcare (THC) to $210 from $175 and keeps an Overweight rating on the shares. Tenet’s higher margins, improving free cash flow, and strengthened balance sheet reinforce the case for a re-rating, according to the analyst, who calls out Tenet as the firm’s preferred stock in hospitals.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on THC:
- Tenet Healthcare Appoints Lisa Y. Foo as COO
- 3 Undervalued Stocks to Buy Now, 6/5/2025, According to Analysts
- Tenet Healthcare price target raised to $215 from $171 at Barclays
- Court blocks Trump tariffs, Musk steps away from DOGE: Morning Buzz
- Nvidia upgraded, Salesforce downgraded: Wall Street’s top analyst calls